Fortrea (NASDAQ:FTRE) Announces Earnings Results, Beats Estimates By $0.06 EPS

Fortrea (NASDAQ:FTRE) announced its earnings results on Thursday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.22 by $0.06, FiscalAI reports. The firm had revenue of $691.50 million for the quarter, compared to the consensus estimate of $671.57 million. Fortrea had a negative net margin of 2.58% and a positive return on equity of 13.98%.

Here are the key takeaways from Fortrea’s conference call:

• Fortrea raised and narrowed its 2026 outlook, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million, reflecting improved execution and confidence in its return-to-growth strategy.
• Third-quarter adjusted EBITDA rose 14.4% year over year to $58 million, with margin expanding 120 basis points to 8.4% as portfolio mix, cost controls, and efficiency initiatives more than offset higher compensation investments.
• Demand trends improved, with $773 million in net new business awards, a 1.12 times book-to-bill ratio, stronger biotech bookings, and increasing biopharma RFP activity. Management said the broader pipeline and improving market recovery support future growth, although no 2027 guidance was provided.
• Fortrea completed its acquisition of Worldwide Clinical Trials’ Early Phase Services business, expanding its network to more than 570 beds and adding in-house bioanalytical and safety-lab capabilities that management expects to broaden its addressable market and support future profitability.
• Fortrea recorded a cumulative $558 million backlog adjustment, reducing reported backlog to $7.3 billion. Management said the adjustment reflects inactive studies and work no longer expected to be delivered and does not affect current revenue recognition or near- and medium-term planning, but it highlights uncertainty in the long-term backlog.

Fortrea Trading Down 8.0%

Shares of FTRE opened at $21.29 on Friday. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -29.16, a P/E/G ratio of 0.56 and a beta of 1.93. The stock’s 50-day moving average price is $20.28 and its 200 day moving average price is $15.74. The company has a quick ratio of 0.96, a current ratio of 0.97 and a debt-to-equity ratio of 1.94. Fortrea has a 12-month low of $8.55 and a 12-month high of $26.16.

Insider Activity

In related news, CEO Anshul Thakral sold 99,869 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the sale, the chief executive officer owned 316,797 shares in the company, valued at approximately $6,069,830.52. This represents a 23.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.73% of the company’s stock.

Key Headlines Impacting Fortrea

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, above the $0.22 consensus estimate and up from $0.12 a year earlier. Revenue of $691.5 million also exceeded expectations of $671.6 million. Fortrea Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management forecast 2026 revenue of $2.665 billion to $2.690 billion and raised its adjusted EBITDA outlook to $210 million-$218 million, signaling improved expected operating profitability. Fortrea Raises Adjusted EBITDA Outlook
• Positive Sentiment: Barclays raised its price target from $23 to $26 and maintained an “overweight” rating, reflecting increased confidence in Fortrea’s valuation and earnings potential. Barclays Fortrea Rating
• Neutral Sentiment: Despite the earnings beat, Fortrea continues to report a negative net margin, so investors may remain focused on whether the improved EBITDA outlook translates into sustainable bottom-line earnings. Fortrea Third-Quarter Results
• Negative Sentiment: Fortrea shares fell after the results, indicating that investors may have viewed the revised guidance, business outlook, or earnings quality as less compelling than the headline quarterly beat. Fortrea Shares Drop After Q3 Results

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on FTRE shares. William Blair raised Fortrea to a “hold” rating in a research report on Wednesday, July 29th. Truist Financial lifted their price objective on Fortrea from $26.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday. UBS Group boosted their price objective on Fortrea from $22.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. Mizuho increased their target price on Fortrea from $13.00 to $16.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Finally, Evercore reaffirmed an “outperform” rating on shares of Fortrea in a report on Wednesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $23.68.

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.